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COMMUNICATION  FROM  THE  COMMISSION  TO  THE  EUROPEAN  PARLIAMENT 
pursuant  to Article  149:2Cb)  of  the  EEC  Treaty 
Com~on positions of  the  Counci1  on  four  proposals  f6r  directives 
on.mcdicinal  produ,cts  fer  human  use: 
Proposal  for  ~  Counci I  Directive on  the  wholesale distribution of 
medicinal  products  for  human  use  (SYN  229) 
Proposal-for  a  Counci'l  Directive on  the  !egai  status  for  the  supply of 
medicinal  products  for  human  use  (SYN  230) 
Ptoposa!  for  a  Council ,Directive on  the .label I ing  of  medicinal  products 
.  .  .  '  .  .  .  .  . 
for· human  use  and  for  pack~ge  leafl~ts  (SYN  231) 
Proposa I  for  a  Counc i I  D  ired i ve  on  the  advertising of  medici na.l 
products  for  human·use  (SYN  273) 
,,  _______ -· -------------· ,,  __  ,  ___  c - 2  -
COMMUNICATION  FROM  THE  COMMISSION  TO  PARLIAMENT 
On  26  January  1990  the  Commission  sent  the  Counci I  three  proposals  for 
directives on  the  rational  use of medicinal  products  (COMC89)607  final): 
Proposal  for~ Council  D1rective  on  the wholesale  distribution of 
medicinal  products  for  human  use  (SYN  229) 
Proposal  for  a  Counci I  Directive on  the  legal  status  for  the  supply 
medicinal  products  for  human  use  (SYN  230) 
Proposal  for  a  Counci I  Directive on  the  labelling of  medicinal  products 
for  human  use  and  for  package  leaflets  (SYN  231) 
On  6  June  1990  the  Commission  furthermore  sent  it  a  proposal  for  a  Counci I 
Directive on  the  advertising of  medicinal  products  for  human  use  (SYN  273) 
(COM(90)212  final). 
In  the  light  of  Pari iament's opinions of  12  June  1991  on  these  four 
proposals,  the  Commission  amended  its proposals  on  18  July  1991  (COM(91)245 
f ina I). 
On~'\ October  1991  the Counci I  adopted  common  positions on  these  four 
proposals. 
The  Commission  hereby  submits  the  following  comments  to  Pari iament  in 
accordance  with  Article  149(2)(b)  of  the  EEC  Treaty. - 3  -
~0fflmission comments  on  the Council·s common  position on  the wholesale 
distribution of medicinal  products  for  human  use 
1.  General 
(SYN  229) 
For  the  most  part,  the Council's  common  position  is  in  I ine  with  the 
Commission's original  proposal.  The  main  amendment  by  the Counci I 
corresponds  to  an  amendment  by  Parliament  which  the  Commission  had  included 
in  its amended  proposal  (see  point  3  below). 
2.  Links  between  authorization of  manufacture  and  authorization of 
distribution 
Parliament  had  proposed  spel I ing out,  in  a  recital,  the  relationship 
b0tween  the  authorization  to manufacture  medicinal  products  (provided  for 
ir1  Article  16  of  Directive 75/319/EEC),  authorization  for  the  wholesale 
distribution of  medicinal  products,  and  authorization  for  the  supply of 
medicinal  products  to  the  public.  The  Counci I  adopted  these  detai Is  but 
incorporated  them  in  the  body  of  the  directive  (Article  3(2)  and  (3)). 
3.  Public  service obi igations 
The  Commission  had  included,  in  its amended  proposal,  a  definition of 
public  service obi igations  (Article  1(2a)  and  the principle  that  these 
obligations  are  not  affected  by  the  directive under  consideration 
(Article 7).  The  Counci I  adopted  the  definition but  retained  the  text  of 
the  Commission's  initial  proposal  as  regards  Article 7.  Furthermore,  the 
Council  made  it  clear  that  the  public service obligations  cannot  be  imposed 
on  a  wholesaler  established  in  another  Member  States unless  these 
obi iJations  are  justified on  grounds  of  public health  protection  and  are  in 
proportic.~ to  the objective of  protection.  The  Commission  has  accepted 
tl1is  ajdit ion,  which  merely  embodies  a  general  principle of  Community  law. • 
- 4  -
4.  Reference to  the  batch  number  in the documents. retained .by  wholesalers 
The·counc·i·l-has  deleted  the  ba-tch  number  from  the--information  which  must  _____  _ 
appear  in  the  documents  reta.ined  by  wholesalers  (Article 6(e)).  This 
deletion  had  been  reQuested  by  Parliament  but  the  Commission  had  not 
included  it  in  its proposal.  The  Counci I  and  the  Commission  have  agreed, .. 
in  a  statement  in  the minutes,  that  the Question of·the·batch  number  wi  I 1 
be  dealt  with  in  the  framework-of  the guidelines  referred  to  in  Articl.e  10. 
5.  Publication of  guidelines 
In  its amended  proposal,  the  Commission  proposed,  as. suggested  by 
Parliament,  a  period of  two  years  for  the  publication of  the  guidelines 
referred  to  in  Article  10.  The  Council  has  not  specified  any  period.·. This 
~il I  obviously  not  prevent  the  Commission  from  publishing the guidelines 
within  two  years of  adoption of  the  directive. 
6.  Entry  into  force  of  the  directive 
The  council  has  postponed  the entry  into force of  the directive  by  one  year .. 
(1  January  1993  instead of  1  January  1992).  This  postponement·would·seem 
.•• ·;·, f'  -··~  tO  be  essent i a r  i·n  view of· the. time  wh i'ch  has  eJapsed.:·.;s i nee  ·the: ~Commission 
put  forward  its.proposal. - 5  -
Commission  comments  on the council's common  position on  the  legal  status 
for  the supply of medicinal  products for  human  use  (SYN  230) 
1.  General 
The  Council's common  position·  includes most  of  the  amendments  which  the 
commission made  to  its proposal  in  the  light of Parliament's opinion. 
2.  Subcategories of medicinal  products  avai table on  prescription only 
The  Counci 1  has  adopted,  as  provided  for  in  the  amended  proposal,  two 
subcategories of medicinal  products  available on  prescription only 
(Article  3(2)  and  (3)).  The  common  position specifies  that  the  competent 
authorities may  waive  the  application of  these  subcategories under  certain 
conditions which  are specified  (Article 3(4)).  Furthermore,  it  lays  down 
that,  where  a  Member  State does  not  introduce  the subcategories,  it must 
nevertheless  take  account  of  the criteria referred  to  in  paragraphs  2  and  3 
of  Article  3  to  determine whether  a  medicinal  product  should  be  included 
among  the  category of  products supplied on  prescription only.  These 
additions are  in  keeping  with  the  sp~rit of  the  amended  proposal  and  the 
Commission  therefore  accepts  them. 
3.  Clarification with  regard  to classification  in  the marketing 
authorization file 
The  common  position does  not  specify  that  the  legal  status of  supply  of  a 
medicinal  product  and  its classification are  to  be  set  out  in  the  marketing 
authorization  and  included  in  the  summary  of  the  product  characteristics 
(Article  4  of  the  amended  proposal).  The  Counci I  has  taken  the  view  that 
this should  be  included  in  the  correspondirig provisions of 
Directive 65/65/EEC  (Articles  4  and  4a)  and  the Commission  has  accepted 
this  viewpoint. 
• 
• • 
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4.  Establishment  of  common  lists 
In  its common  position,  the-:Counc·il·.has-not:provided  for  the  establ-ishment 
by.  the  Commissl.on,  within  five  years of  the  adoption  of  the  direct.ive,  of 
common  lists of  medicinal  products available on  prescription only  and  of 
-those which  ar~·avallable.wlthout medical  prescri~tlon (Article -5{3)  and 
(4)  of  the  amended  proposal) ..  The  Councll.has  not  accepted  this provision, 
·but  has  laid down  that,.wi·thin  four  years,  the  Commission  is  to  report  to 
it on  the  application of  the  directive,  the  report  being  accompan~ed,  if 
necessary,  by  appropriate  proposals. 
5.  Entry  Jnto  force of the directi.ve 
"The  Council  has  postponed  the entry  i.nto  force-of  the-directive  by  one  year 
(1  January  1993  instead of  1  January  1992).- This  postponement ~ould seem 
to be  essential .in  view  of  the  time  which  has elapsed since  the  Commiss-ion 
put  forward  Its proposal. - 7  -
Commission  comments  on  the Counc i I 's common  pos i tlon of  the  Counc i I  on  the 
labelling of medicinal  products  for  human  use  andon  package  leaflets 
(SYN  231) 
1.  General 
The  common  position contains several  amendments  to  the  amended  proposal. 
Th~ amendments  are mostly  technical  and  are main1y  aimed  at  specifying  the 
obi igations  under  the Directive.  The  Commission  therefore accepts  the 
common  position. 
2.  Definitions 
The  Counc i I  has  added  a  defInition of  the dose of  a  medici n·a I  product  and  a 
definition of  the manufacturer  to  the definitions appearing  in  the  amended 
proposal.  The  Commission  believes  these  two  additions are useful. 
3.  Deletion of Article 2 
The  Counci I  has  taken  the  view  that  it  is  not  neces~ary to state  that  an 
unauthorized medicinal  product  may  not  be  authorized:  The  Commission  shares 
this  viewpoint,  the  p.rincipl·e of  which  is already  included  in  Community  Jaw 
(Article  3 of  Directive 65/65/EEC). 
4.  Compulsory  labelling 
The  Council's  common  position  (Article  2)  adds  four  additional  points of 
detai I  to  the  amended  proposal  (Article 3): 
where  there  are  several  pharmaceutical  forms  or  several  doses  for  a 
medicinal  product,  the  pharmaceutical  form  or  dose  is  to be  included  in 
the  name  of  the  medicinal  product  (paragraph  1(a)), 
all  of  the excipients are  to be  mentioned  in  the case of  an  injectable 
product,  a  topical  preparation or  an  eyewash  (paragraph  1(d)), 
• - 8  -
-·  where  a  speciaJ  warning  is  required,  it·~s to appear  on  the  label 1 ing 
(paragraph  1(g)), 
for  medicinal  products  for  self-medication,  information-regarding use-is 
to appear  on  the· I  abe Ill ng  (paragraph  Hn)  ).~ 
The  Commission  has  accepted  these  four  points of  detail  which  are·in 
keeping  with  Its amended  proposal. 
5.  Lab-elling  part lculars 
-The  Council's  common  posltion·does  away.with  the·need  to  include.certain. 
particulars  in  the  same  visual.area  (Arti-cle  5(2.) .of  the  proposal)  and 
states ·that  the outer  packaging  may  include  symbols  or  pictogrammes  usefu,l 
for  heal·th·education  but  not  any  promotional  material  (Article  2(:2)  of  the: 
common  position).  These  amendments  bring  the  Iabeii ing  provis.ions  into  I ine 
with  those  for  the  leaflet. 
6.  Package  leaflet 
·The  common  position  (Article 7)  contains only minor  amendments  as  regards 
.the  package  leaflet  as  compared-with  the  amended  proposal. 
7.  Guide I i nes 
The·common··posit·ion~(Article 12)  does  not  lay  any  deadl·:ine  for  the  adoption··  :. 
of,guidel ines.  However·;  it  does  speci·fy  that  these  guide I ines  are  to .be 
adopt~d-1n the  form  of~ directive sent  to  the  Member  States  in  accordance 
with  the  procedure  laid  down  .in  Article  2(d)  of  Dir~ctive 75/318/EEC.  As 
the  measures· to  be  taken  are  regulatory  and  the  procedure  concerned  is 
customary  ~n the  field of  medicinal  products  for  human  use,  the  Commission 
has  accepted  this  amendment. - 9  -
8.  Entry  into  force of  the Directive-
T·he  Council  has  postponed  the entry  into  force  of  the directive  by  one  year 
(1  January  1993  and  1  January  1994  instead of  1  January  1992  and 
1  January  1993  respectively).  This  postponement  would  seem  to  be  essential 
in  view of  the  time  ~hich has elapsed since  the-commission  put  fo~ward  its 
proposal. 
f 
-~-
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·Commission  comments  on  the  Counci.l's  common  position on 
the  advertising of  medicinal  products  for  human-use 
l. Genera I 
(SYN-273) 
The  Council's  common  position contains several  major  amendments  as  compared 
with  the Commission's. amended  proposal  as  it  leaves  a  number.  of  matters 
(the  authorization of  reminder  advertising,  indication of  the  sales· price 
·in publicity supplied  to -professionals,  the  number  of  free  samples-which 
may  be  given  to  health  care professionals)  to  the  discreti~n of  the 
Member  States.  However,  the Commission  has  accepted  these  amendmentsi 
taking  the  view  that they  do  not  distort  the  general.  batance of  the text 
and  they  reflect  the still  profound differences between  medical  conventions 
in  the  various Member  States,  that the differences  between  the  national 
laws  which  may  result  will  not  affect  the  functioning of  the  internal 
market  and  that  fuller  harmonization  can  take  place at  a  later  date  if  the· 
need  is  felt. 
2.  Definitions 
The  common  position  def-ines  the  "advertising of medicinal  ~roducts" and 
1 ists various  forms  of  advertising  (Article 1(3)).  It  also refers  to 
certain forms  of  communication  which  are  not  considered  to  be  covered  by 
the  directive  (Article 1(4)).  The  Commission-has  accepted  these  amendments 
which  add  useful. addJtional  information  as  regards  the  scope  of  the 
directive without  narrowing or  widening  it. 
3.  Medicinal  products  w~ich may  be  advertised  to  the  public 
·The  common  position  retains the  principle on  which  the  Commission's amended 
. proposal  was  based.  However,  it defines  sel.f-medi·cation  (Article  3(2))  and - 11  -
allows  the Member  States to prohibit  the  adver~isin~ of  medi~inal  products 
subject  to  reimbursement  and  to authorize  the  direct  distribution of 
medicinal  products  to  the  public  in  exceptional  cases  and  for  non-
promotional  purposes.  The  common  position does  not  expressly prohibit  the 
advertising  to  the  public of  medicinal  products which  are  habit-forming or 
-~  -
addictive  (Article 3(1)  of  the  amended  proposal).  However,  it  should  be 
borne  in  mind  that  such  medicinal  products  wi  I I  normally  be  available on 
medical  prescription only  and  that  advertising of  them  wil I  therefore  be 
prohibited. 
4.  Reminder  ~dvertising 
The  common  position ,allows  the Member  States  to authorize  reminder 
advertising  to  the  public  (Art'icle 4(2)).  The  Commission  had  already 
informed  Pari lament  that  it was  itself  not  opposed  to such  authorization. 
5.  Prohibition of certain forms  of  advertising 
The  Council  has  extended  the  list of  forms  of  advertising  to  the  public 
which  are prohibited  (Article 5(1),  (J),  (k),  (I)).  The  addition actually 
i I lustrates  the general  principle  that  the  advertising of medicinal 
products must  promote  their·rational  use  and  may  not  be  misleading. 
6.  Sponsorship of  promotional  events 
With  regard  to  the  sponsorship of scientific congresses,  the  common 
position  (Article 10)  includes what  is set out  in  the  amended  proposal  in 
the  light of  Parliament's opinion.  Furthermore,  the  common  position extends 
this principle  to  promotional  events  for  medicinal  products  (Article 9(2)). 
This  does  not  create any 'problems. - 12  -
7.  Free  samples 
The  amended  proposa I  I im i ted  the  number  of  free  samp 1 es  wh  i c!1  may  be  given 
each  year  to  any  doctor  to  2.  The  common  position states.that only  a 
"I imited  number"  of  samples  may  be  given,  thereby  allowing  the 
Member  States  a  certain degree of  flexibility  in  applying  the  principle. 
While  it  believes  that  it  would  have  been  better  to state specifically  in 
the  directive  the  number  of  samples  which  may  be  given  away,  the  Commission 
agrees  that  monitoring  of  the  comp.l  iance  with  such  a  provision  would  be 
difficult  and  that  a  s1ight  divergence  in the application of  this  rule  is 
.of  no  consequence  as  regards  the  functioning  of  the  internal  market. 
8.  Monitoring  of  advertising 
First,  the  common  position states  that  the  means  used  by  the  Member  States 
to monitor  the  advertising of  medicinal  products  may  be  based  on  a  system 
of  prior  control  (Article  12(1)).  This  point  of  detai 1,  which  is  in  keeping 
with  Pari lament's  request,  does  not  pose  any  problems  for  the  Commission. 
Second,  the  Counci I  has  aligned  the  provisions  on  monitoring of  the 
advertising of  medicinal  products  (Article  12(2))  with  those  in 
Directive  84/450/EEC  on  misleading  advertising  (Article 4(2)).  This 
so:ution  has  the  advantage  of  harmonizing  the  provisions  under  Community 
law  on  the  monitoring  of  advertising. 
9.  Entry  into  force  of  the  Directive 
The  Council  has  postponed  the entry  into  force  of  the  Directive  by  one  year 
(I  January  199::  instead  of  1  January  1992).  This  postponement  would  seem  to 
:;,:;essential  in  view  of  the  time  which  has  elapsecl  since  the  Commission  put 
forward  its proposal. 